Objective
To restore islet function in patients whose labile diabetes subjected them to frequent dangerous episodes of hypoglycemic unawareness, and to determine whether multiple transplants are always required to achieve insulin independence.
Summary Background Data
The recent report by the Edmonton group documenting restoration of insulin independence by islet transplantation in seven consecutive patients with type 1 diabetes differed from previous worldwide experience of only sporadic success. In the Edmonton patients, the transplanted islet mass critical for success was approximately more than 9,000 IEq/kg of recipient body weight and required two or three separate transplants of islets isolated from two to four cadaveric donors. Whether the success of the Edmonton group can be recapitulated by others, and whether repeated transplants using multiple donors will be a universal requirement for success have not been reported.
Methods
The authors report their treatment with islet transplantation of nine patients whose labile type 1 diabetes was characterized by frequent episodes of dangerous hypoglycemia.
Results
In each of the seven patients who have completed the treatment protocol (i.e., one or if necessary a second islet transplant), insulin independence has been achieved. In five of the seven patients only a single infusion of islets was required. To date, only one recipient has subsequently lost graft function, after an initially successful transplant. This patient suffered recurrent hyperglycemia 9 months after the transplant.
Conclusions
This report confirms the efficacy of the Edmonton immunosuppressive regimen and indicates that insulin independence can often be achieved by a single transplant of sufficient islet mass.
Type 1 diabetes afflicts nearly 2 million Americans and is responsible for untold human suffering and healthcare resource consumption. In the 1960s, Kelley et al. demonstrated that the hyperglycemia of diabetes could be reversed by transplantation of a vascularized whole organ pancreatic allograft. 1 Since that time more than 15,000 diabetics have been treated by this method. 2 There is strong evidence that complete and lasting restoration of glucose homeostasis provided by successful pancreatic transplantation retards and possibly even reverses some of the secondary complications of the disease. [3] [4] [5] [6] [7] [8] [9] [10] [11] Nevertheless, despite the benefits of successful whole organ pancreas transplantation, it is a major operation of considerable risk. 12 In addition, it has substantial technical difficulties, most notably thrombosis of the graft's artery or vein, which results in the loss of 5% to 10% of pancreas transplants. 2 Because of the risks involved in vascularized pancreas transplantation, it is generally considered to be indicated for relatively few of the many patients with type 1 diabetes.
Successful transplantation of isolated pancreatic islets in experimental animals was first reported in 1972. 13, 14 This approach is conceptually attractive as it not only avoids complications related to the exocrine pancreas and blood supply of whole organ pancreas grafts, but might also allow pretransplant manipulation of the graft to decrease its immunogenicity. Over the next 30 years enthusiasm for attempts at human islet transplantation was consistently thwarted by the failure of almost all clinical islet transplants, few of which reversed hyperglycemia even transiently. In 1999 a summary of International Islet Registry data indicated that the 1-year survival of isolated islet transplants in humans was less than 10%. 15 Interest in isolated islet transplantation was revitalized in 1999 by reports of several successes from the University of Giessen. 16 In 2000, even better results were accomplished by Canadian investigators, who reported reversal of hyperglycemia in seven consecutive islet transplant recipients. 17 The reasons for the striking improvement of the Canadian group over earlier results remain unclear but likely include their use of a novel immunosuppression regimen (in which agents with known islet toxicity were omitted or minimized) and employment of multiple transplants (two or three in the same recipients), since a single transplant did not usually accomplish normoglycemia. Earlier workers had usually considered islet transplantation as a failure when insulin independence was not achieved with a single dose and had withdrawn immunosuppression without considering retransplantation. In the Edmonton series reported to date, more than 17 consecutive patients have achieved insulin independence if a transplanted islet mass of more than 9,000 IEq/kg of recipient body weight has been reached. 18, 19 However, to achieve this level of islet mass, two or three infusions of islets isolated from a total of two to four donors have been required.
Because the number of cadaveric donors is inadequate to treat the increasing numbers of individuals on organ transplant waiting lists, isolated islet transplantation is unlikely to become practical for treatment of diabetes if each recipient requires islets from several donors, especially since whole pancreas transplantation requires only a single donor organ. Thus, it is essential that the experience of the Edmonton investigators be validated by other centers not only in terms of the effectiveness of the novel immunosuppressive protocol but also in the need for multiple transplants. A large multicenter trial conducted through the Immune Tolerance Network has been funded by NIH in an attempt to corroborate the findings by these Edmonton workers.
In this report, we describe our experience using the Edmonton immunosuppressive regimen in nine type 1 diabetic patients. Insulin independence was achieved in each of the seven patients who have completed the protocol. Unlike the Edmonton experience, however, in five cases success was achieved using a single infusion of islets, of which three preparations consisted of islets prepared from a single pancreas.
METHODS

Recovery of Donor Pancreas and Islet Isolation Procedure
Between February 2000 and December 2002, we processed 144 human pancreases for islets. Islets from 23 pancreases were isolated with the intent to transplant. Of these, 15 preparations were deemed suitable for transplantation and infused into nine patients. The first clinical transplant was performed in September 2001. Donor characteristics are detailed in Table 1 . Pancreases were harvested using standard multiorgan recovery techniques. In brief, the pancreas was removed following recovery of thoracic organs and the liver. UW solution was used for preservation of all organs. The two-layer perfluorocarbon technique was not used, nor were protease inhibitors. In 1 case, islets from a non-heart-beating donor (NHBD) were transplanted, and in 14, standard brain-dead donors were the source of the pancreases from which islets were isolated. In the NHBD case, total warm ischemia time was 25 minutes. Our in vitro studies of islets isolated from 10 NHBDs (detailed elsewhere) suggest that they are usually suitable for transplantation if warm ischemia time is less than 30 minutes. 20 Pancreatic islets were isolated using a modification of the automated Ricordi method. 21 Liberase (0.5 g) in Hanks' BSS 22 was infused into the main pancreatic duct using a hand-held syringe and a Webster cannula. The Ricordi chamber was agitated with a mechanical shaker to facilitate the digestion process. Islets were resuspended in UW solution and separated from contaminating exocrine tissue using the COBE 2991 (not refrigerated) and a top-loaded continuous Ficoll gradient (density range 1.055-1.120). UW solution was used as the light density solution for preparation of the density gradient, and islets were added directly to the gradient while suspended in UW solution containing 5% human serum albumin (HSA). The isolation process was performed without xenogeneic serum, since, as suggested by Shapiro et al., this might lead to their increased susceptibility to immune damage. 17 Islets were temporarily cultured in vitro before in vitro assessment of their viability and functional status. Single-donor preparations were transplanted as soon as possible after isolation. When islets from two donors were combined (n ϭ 3) for the same infusion, the first isolate was cultured in vitro at 24°C (3-9 hours) until islets from the second pancreas were ready for transplantation.
Pretransplant Evaluation of Donor Islets
To be deemed suitable for clinical transplantation, islet preparations had to meet the following criteria: 1) viability at least 70%, 2) purity at least 30%, 3) number at least 4,000/IEq kg of recipient, 4) packed tissue volume of less than 10 mL, and 5) endotoxin level of less than 5 EU/kg recipient/h of infusion (isolated islet preparations were infused over 20 -60 minutes). In addition, the preparation had to be negative for microorganisms by Gram stain. Posttransplant assessment of the preparation also included standard cultures for bacteria and fungus, all of which proved to be negative. All islet preparations had a packed tissue volume of no more than 5 mL.
Indications for Clinical Islet Transplantation
To be accepted for islet transplantation patients had to have the following characteristics: 1) type 1 diabetes of a least 5 years' duration; 2) a history of multiple episodes of dangerously severe hypoglycemic unawareness requiring hospitalization despite optimal management by an experienced diabetologist; 3) undetectable C-peptide levels measured 90 minutes after "mixed-meal" stimulation by ingestion of 360 mL Boost (540 calories). Other recipient characteristics are detailed in Table 1 .
Islet Transplant Procedure
Islets were transplanted following suspension in CMRL media supplemented with 5% HSA and heparin (35 U/kg recipient body weight). Islets were infused into the liver following percutaneous angiographic cannulation of the main portal vein under fluoroscopy and ultrasound. During infusion, the portal pressure was monitored at least every 5 minutes. After infusion the catheter was removed and a Gelfoam plug was left in the hepatic parenchymal tract to reduce the risk of postprocedural hemorrhage.
Recipient immunosuppression was similar to that described by Edmonton [17] [18] [19] : Zenapax (2 mg/kg IV) was given immediately before transplant and then every 2 weeks for four additional doses (1 mg/kg); rapamycin (loading dose of 0.2 mg/kg, then 0.1 mg/kg daily), with a target trough of 12 to 15 g/mL for the first 3 months and 7 to 10 g/mL thereafter; and tacrolimus (1-4 mg twice daily), with a target trough level of 2 to 5 g/mL.
Posttransplant Assessment of Islet Function
Patients were monitored with serial laboratory tests every 8 hours ϫ 4 following the procedure, and blood glucose was determined hourly for the first 12 hours. At varying times before transplant, patients recorded seven daily blood glucose levels on 2 separate days (blood glucose was checked before and 2 hours after each meal and at bedtime). A similar glucose-monitoring schedule was performed daily for the first 3 months after transplant. At 3, 6, and 9 months posttransplant, the blood glucose level 1.5 hours after a Boost challenge was measured, as were serum C-peptide levels before and after "mixed-meal" ingestion.
RESULTS
Experience in Islet Isolation
Our experience with 144 islet isolations demonstrated a steep learning curve (Fig. 1) . The mean yield of the first 50 isolations was 194,349 IEq's; that of the last 50 isolations was 414,788 IEq's. These results include those of all pancreases procured, including those from donors not typically considered suitable for pancreas or transplantation such as NHBDs (n ϭ 10), donors with type 2 diabetes (n ϭ 13), and donors age 65 and older (n ϭ 12). The improvement in yield over time was also likely influenced by the selection of better donors later in the experience, since the intent was more often for transplantation rather than for developing the optimal processing protocol or strictly for research interests. The apparent cyclical nature of the average yield appears to be a consequence of changes in the lot of Liberase used for the isolation, which is generally purchased in 30-to 40-unit batches. On completion of a batch there is an obligatory period of testing new lots until a suitable preparation is identified. During this period of testing the yield may be reduced and more variable.
Outcome of Islet Isolation When Pancreases Are Processed With the Intent to Transplant
Of 144 total isolations performed, 23 were initiated with the intent for use in clinical transplantation. Of these, eight were found not suitable for clinical use because the islets isolated were of insufficient quantity (n ϭ 6) or quality (n ϭ 2). Interestingly, those islets that proved unsuitable for transplant tended to be from younger donors (mean ϭ 37 vs. 50 years of age) or from smaller donors (weight 83 vs. 99 kg, BMI 26.5 vs. 33.8).
Evidence from recent analysis of patients transplanted in Edmonton indicates that prolonged ischemia of islets may adversely impact their function posttransplant in vivo. 18 Thus, we made every effort to minimize the time from donor cross-clamp to transplantation. Figure 2 details the duration of cold ischemia (from cross-clamp to beginning processing) and the total ischemia time (from cross-clamping in the donor until infusion in the recipient). Cold ischemia time for all preparations was less than 8 hours, and total ischemia time was less than 16 hours for all singledonor preparations. When islets from two donors were combined for simultaneous transplantation, there was an additional obligatory ischemia for the first preparation while the second isolation was performed. The duration of in vitro storage in culture of the first isolate for three such combined preparations was 3.0, 5.5, and 9.0 hours.
Pretransplant Evaluation of Isolated Islet
A variety of tests were performed on each islet preparation in an attempt to predict the outcome of isolated islet transplantation. The first assessment involved inspection of the preparation under a dissection microscope and assignment of a subjective quality score based on five parameters: shape, size, presence of single cells, regularity of the boarder, and integrity of the islet (0, 1, or 2 points awarded Shown is the cold ischemia time, from cross-clamp in the donor to initiation of the isolation procedure (blue bar) for the 15 isolations that have been transplanted. Red bars indicate the total ischemia time from cross-clamp to infusion of the preparation in the recipient. Three preparations (10, 12, and 14) were transiently maintained in vitro while a second isolation was performed. Total in vitro culture was 3, 5.5, and 9 hours, respectively.
for each parameter). Only preparations receiving a score of at least 7 were accepted for transplant.
Historically, the most frequently used assay of islet function has been static incubation measuring the change in release of insulin by a defined number of islets suspended in media in which the glucose concentration is changed from 2.8 mmol to 20 mmol. The average stimulation index of transplanted preparations was 1.6. In our experience, this assay has not proved to be a reliable predictor of posttransplant function.
Results of Isolated Islet Transplantation
Of the nine patients transplanted, seven patients completed the protocol that called for two islet transplants (unless one transplant resulted in normoglycemia). All seven of these patients achieved insulin independence. One other patient recently transplanted is not normoglycemia and awaits retransplantation (currently on one third of the pretransplant insulin dose and free of hypoglycemic events), and one patient was withdrawn from the study before receiving a second infusion, as detailed below. Of the seven who developed insulin independence, five required only a single infusion of islets and two gained insulin independence after a second infusion. Of the five preparations that rendered the recipient insulin-independent after a single infusion, three comprised islets from a single donor and two comprised islets combined from two donors.
Of the seven patients who became insulin-independent, six remain so. In one patient, the majority of graft function was lost about 8 months after islet transplantation, requiring resumption of insulin therapy. In the recipient of this failed transplant, the C-peptide level remains above zero (5-1.0 ng/mL). This patient currently requires half of his pretransplant insulin dose, suggesting that some graft function may remain. Of note, this patient demonstrated a gradual increase in fasting glucose levels before overt hyperglycemia (Fig. 3) . Whether graft dysfunction in this case resulted from graft rejection, autoimmune recurrence, or graft exhaustion is under study. The patient has not demonstrated serologic evidence of sensitization to donor HLA antigens to date, but this may be due to masking by the continued administration of immunosuppression.
One of the patients who became insulin-independent following a single-donor transplant developed mild fasting hyperglycemia 9 months posttransplant despite a C-peptide level indicating stable, excellent islet function (stimulated C-peptide 3.3-4.0 ng/mL). This patient received a second infusion at 12.5 months and has gained excellent control.
The details of the 15 islet preparations used for transplantation are summarized in Table 2 . The average number of IEq's per isolation was 536,600. This translated into 8,246 IEq's per kg per infusion. In five instances, a single infusion (three comprising one donor, one comprising two donors) resulted in insulin independence. In these cases, the average total number of IEq's infused was 616,200 and 9,282 IEq/kg recipient. In the four cases in which a single infusion did not result in insulin independence, the average number of IEq's infused was 603,250 (8, 112 IEq/kg recipient). Two of these patients subsequently became insulin-independent following repeat single-donor infusion, and one patient awaits retransplantation.
One patient who failed to achieve insulin independence following a single-donor infusion of 9,700 IEq's/kg recipient had to be withdrawn from the study 3.5 months later (before retransplantation) due to a nonhealing traumatic foot wound because of a concern that rapamycin was preventing healing. (This patient was excluded from the survival analysis since the planned second islet transplant was not possible.)
Recipient Glucose Control Posttransplantation
Insulin-independent transplant recipients were followed by C-peptide levels, hemoglobin A1c (HgbA1c) measurements, and mixed-meal challenges. The mixed-meal challenge demonstrated excellent graft function, as evidenced by a rise in C-peptide after the mixed meal. Glucose disposal was mildly abnormal in some recipients, as evidenced by a mildly elevated fasting glucose level (110 -126) and by an elevated glucose at 90 minutes after the mixed-meal challenge. Similarly, successful islet transplantation was associated with a normalization of HgbA1c levels (Fig. 4) . 
Immunologic Consequences of Islet Transplantation
All patients were evaluated for panel reactive antibodies (PRA) before transplantation and were found to have zero PRA activity. Another cross-match of the pretransplant serum taken from each recipient against the donor's lymphocytes was also negative. All patients have remained PRA negative posttransplant except for the patient who, because of withdrawal from the study, had immunosuppression terminated. This patient now has weakly reactive antibody to donor HLA class I and class II antigens by flow cytometry.
Complications
No life-threatening or otherwise serious complications have occurred, but a variety of minor complications have been observed related either to the transplant procedure or the posttransplant medications (Fig. 5) . Development of month ulcerations, presumably due to rapamycin, was universal in the first 3 months, when the highest levels were maintained. All ulcers responded spontaneously to dose reduction. Mild hematologic abnormalities were also commonly seen in the early posttransplant period, including mild leukopenia (WBC Ͻ 4.0), mild anemia (Hgb Ͻ 11.8), and mild thrombocytopenia (platelets Ͻ 150). Abnormalities in liver function tests occurred in all patients following transplantation but resolved spontaneously. Two patients experienced a marked transient elevation in transaminase levels (Ͼ500) that appeared to have been associated with difficult portal vein cannulation procedures. No cases of serious infections, CMV, or PTLD have been observed.
DISCUSSION
Reports of successful islet transplantation at the University of Giessen and subsequently the even more impressively consistent ones by the Edmonton group renewed interest in clinical application of this therapy for type 1 diabetics. [15] [16] [17] Perhaps of equal importance to the success of the Edmonton series is the definition by the experience of several remaining barriers that could preclude widespread application of the procedure to the majority of type 1 diabetics. In addition to developing protocols that avoid intensive and chronic immunosuppression (a hope for recipients of all transplants), several needed advances are specific to islet transplantation. These include improvements in the isolation and transplant procedure to allow transplantation of a larger number of patients from the limited number of cadaveric organs. In the initial Edmonton reports, islets harvested from 16 donors were required to achieve insulin independence in seven recipients. 17 This 
Figure 4.
Mean serum HgbA1c levels (%) are shown for patients who gained insulin independence before (n ϭ 4) and 3 (n ϭ 4), 6 (n ϭ 4), 9 (n ϭ 3), and 12 months (n ϭ 2) posttransplant.
may significantly underestimate the actual number of donors required per recipient, as it does not include those donor pancreases processed for transplantation but from which the preparation was not suitable for transplantation.
Inclusion of these failed isolations may double the total number of donors procured per recipient. If these difficulties are not overcome, the cost alone of multiple donors per recipient may in itself impede widespread application of islet transplantation as an accepted therapy. This report provides the first formal confirmation of the efficacy of the Edmonton immunosuppression protocol. It is also the first report in which insulin independence was achieved by a single islet transplant with islets isolated from one or two donors in preuremic diabetic recipients. 23 The current results also corroborate the required threshold suggested by the Edmonton workers of IEq's per kg of recipient needed to gain insulin independence. That we succeeded in some patients with one transplant while the Edmonton group and others required multiple transplants is probably related to the larger number of islets we isolated from each donor pancreas than the Edmonton workers. In the Edmonton series, on average each infusion comprised approximately 360,000 IEq. 17 In the present series, we averaged more than 540,000 IEq per infusion. The reasons underlying this difference are not entirely clear but may include slight differences in the isolation technique and, perhaps more likely, differences in donor selection and availability and shorter ischemia time. One unusual aspect of our series of donors is that that average BMI exceeded 31. Intuitively it does not seem surprising that a larger individual might have a pancreas exhibiting greater islet mass. These factors are also evident in comparing the characteristics of single infusions that resulted in insulin independence with those that did not ( Human Islet Transplantation used for islet isolation in the current series were declined for use as whole organ grafts both regionally and nationally. In most cases, the reason pancreases were considered unsuitable for whole organ transplantation was either advanced age or fatty infiltration of the gland. In the three attempts at isolation of islet for transplantation from donors less than 30 years of age, none of the isolations yielded a suitable preparation. Thus, at present, there is a beneficial dichotomy in terms of which pancreatic donors supply optimal organs for whole organ versus isolated islet transplantation. The use of preparations combining islets from more than one donor has a number of practical advantages in addition to simply increasing the transplanted islet mass. First, it has allowed us to use islet preparations that alone would not have constituted an adequate mass for transplantation. In each of the three combined procedures to date, one of the two isolates would alone have been discarded for transplantation because of inadequate number. Second, it may decrease risk to the recipient by reducing the chances that a second infusion procedure is required. Recent data from Shapiro et al. suggest that second and subsequent infusions may be associated with a greater rise in portal pressures that could conceivably be associated with a greater risk of complications such as portal vein thrombosis. 24 In the present study, we combined preparations only when two suitable donors became available simultaneously. It is possible that this strategy could be exploited more extensively by maintaining preparations in vitro for longer periods of time to increase the chances of a second organ becoming available.
Although we succeeded in achieving insulin independence with single-donor infusions in a third of cases, longerterm results suggest that unless even larger numbers of islets can be obtained from each pancreas, in the majority of cases multiple donors may be required. In the three patients who initially exhibited insulin independence after transplantation from a single donor, there has been evidence of late instability of function. One graft eventually failed and one patient was retransplanted to avoid the possibility of ongoing graft injury from having a marginal residual islet mass. Whether these occurrences are a result of transplantation of a marginal mass of islets is unclear, as is whether patients receiving single-donor infusions will have a poorer longterm outcome. It may not be coincidental that the two patients mentioned are also the two insulin-independent patients with the smallest total transplanted islet mass. It would not be surprising if an islet mass in excess of that necessary to gain insulin independence would be beneficial over time.
This realization mandates a search for ways to improve the efficiency of the transplant procedure. One approach is to improve engraftment of transplanted islets, of which up to two thirds may be lost in the immediate transplant period. 25 Novel immunosuppression strategies and perhaps genetic modification designed to prevent posttransplant apoptosis may be beneficial. 26, 27 We recently investigated a novel approach to enhance the efficiency of transplanted islet cells by augmenting insulin secretion. 28 We demonstrated that adenovirus-mediated transfer of the human proinsulin gene to human islets doubled their efficiency in glucose-stimulated insulin release perifusion assays. Moreover, when human islets modified in this way were transplanted to diabetic immunodeficient NOD-SCID mice, only half the normal number was required to reverse hyperglycemia. If these results prove applicable to human islet transplantation, it would not only allow transplantation of preparations currently considered to be of inadequate mass, but also would enhance the likelihood of success with single-donor transplants. It is even conceivable that, with further refinements to optimize this approach, a portion of a pancreas could serve to reverse hyperglycemia. This would not only maximize the use of cadaveric organs, but also would potentially open the door to the use of a segment of a pancreas from a live donor.
In summary, we have presented evidence corroborating the efficacy of the Edmonton immunosuppression protocol for human islet transplantation. In addition, we have demonstrated for the first time that insulin independence can be achieved with single infusions of islet preparations from single-donor or combined two-donor preparations. Further improvements in the isolation procedure, the transplant procedure, or the posttransplant immunosuppression protocol are required to minimize the number of donors required for success in each recipient.
Discussion
DR. J. ALEX HALLER, JR. (Baltimore, MD): I rise primarily to compliment Dr. Markmann on a beautiful presentation and to make a comment about the background for this excellent paper. It is not often that we as surgeons have the opportunity to compliment our basic science colleagues. Much of the background work for this cell transplantation came from work done by Sir Peter Medawar and his group in England in the '50s, when they showed it was possible to create tolerance in certain animals by the injection of homograft cells, splenic cells, I believe, into very immature animals with therefore very depressed immune reactivity. These were true cellular chimeras; they actually tolerated cells from other strains. It was on the basis of this work that Medawar and his group were awarded the Nobel Prize for these observations.
The senior author of this paper was one of two surgeons who first worked with a member of that Medawar team. Dr. Rupert Billingham, a Ph.D., came to the Wistar Institute across the street from the Hospital of the University of Pennsylvania and established a transplantation biology group there.
Dr. Barker and I were fortunate enough to work with that group, who were able to show that it was possible to put viable cells from one group of mice into unrelated species across transplantation barriers if there was immune insufficiency in the recipient animals. They were using immature animals that had not yet developed their own immune reactivity.
One of the problems that they had not expected was that in the process of inoculating splenic cells, they also injected lymphocytes. At that time there was no information about T lymphocytes and their ability to react against a new host. They recognized this in rodents, which they called "runt disease," which we now call "graft-versus-host disease" in the human patient.
My comment is to remind us all that we do not always have an opportunity of being bridges from basic science laboratories to bring this type of research to bear on this remarkable series of patients who now have the benefit of having living islet cells transplanted. The biggest problem, as you know, in any transplantation is the availability of the organ. If the patient on standby has a large body mass and a small donor pancreas, there is no question that you will not have the islet cell mass approved by the Edmonton protocol. However, these patients, even with a single transplant, are much improved clinically. Subsequent transplantation achieves complete insulin independence in most cases.
We have done 20 cases with the Edmonton protocol. About 35% do well with a single transplantation. Unfortunately, with the variability of the donor and the islets available, it is not possible to achieve the ideal cell mass. I was impressed that you are using two donors for a single transplant, which I think is ideal if you have organ availability. Congratulations on your success.
DR. HOSEIN SHOKOUH-AMIRI (Memphis, TN): I would like to congratulate the authors for their fine work and also would like to acknowledge the contributions of Drs. Naji and Barker in the field of transplantations. They have been in the forefront of organ and cell transplant, and the transplant community has learned a lot from their fine work.
Regarding islet transplantation, it is very clear that diabetic patients are in need of insulin only, and second the presumed assumption of lesser morbidity with islet transplantation compared to whole organs may become a true reality. But the most important problem facing all organ transplants is the extreme shortage of available organs. The transplant community is
Human Islet Transplantation doing its utmost effort to address these concerns by giving, for example, two lungs to two recipients, splitting a suitable liver from one donor between two recipients, and using living related donors for organ transplants.
The only exception is the islet transplant, which has used in the majority of cases at least two donors and sometimes three to four donors. Yet the real result still is not comparable to whole organ pancreas transplant, which currently has results similar to other solid organ transplants. If one considers the extreme exclusion criteria that currently are used to select a perfect recipient (such as low BMI, absence of cardiac complications, patients with low insulin requirements, etc.), these results will be even more inferior.
The University of Minnesota, through their living related pancreas transplant program, has also shown that half a pancreas, like other organs, is adequate to sustain a good glucose homeostasis. So why do we need several donors to make one recipient insulin-free?
I believe the current method of islet isolation is not going to solve the problem, and alternative methods need to be identified. One needs also to think about the wisdom of why islets have coupled with exocrine acini in a unique organ called a pancreas. Maybe there are trophic factors there which are important to let the islets function properly. Rather than destroying the organ and many of its islets, and giving very small amounts of total islet content of the pancreas and awaiting improved results, these concerns need to be worked out. My questions to you are:
First, don't you think that now we have to reroute our research in islet isolation and purification and use larger animal models close to human beings to verify function of islet transplants in these animals for longer periods of time before we continue clinical islet transplants?
Second, when we have improved our results with islet isolation, only then randomize every patient to either whole organ or islet transplant rather than allocating many of these precious organs to islet transplants, which in my mind still have questionable results?
Lastly, I would like to thank the authors for providing the manuscript to me well in advance of the meeting and thank the Southern Surgical Association for the privilege of the floor.
DR. WILLIAM C. CHAPMAN (St. Louis, MO): My question is similar to the question that Dr. Amiri just brought up. That is, I would like you to speculate, if you could, on whether this technique is likely to gain broad acceptance if multiple donors are required for each patient. In the manuscript there is discussion of some potential strategies that may enhance the success rate for transplantation using single procedures from single donors. I wonder if you could elaborate a little further on these potential strategies.
DR. F. CHARLES BRUNICARDI (Houston, TX): Of the major therapies that we use to treat for diabetes, the major advances were made by surgeons: Dr. Banting, an orthopedic surgeon, discovered insulin; Drs. Kelly and Lillihie performed the first pancreas transplant in 1966; Dr. Sharp and Dr. Ricordi performed the first successful islet cell transplants in 1988; Dr. Shapiro and the Edmonton group recently advanced islet transplantation 2 years ago with the use of a new steroid-free immunosuppressive protocol.
The current obstacles to advancing islet transplantation are the need for life-long immunosuppressive drugs and the shortage of human islets for the treatment of millions of patients with diabetes.
Drs. Markmann, Naji, and Barker are to be congratulated on carrying out this outstanding study in the spirit of surgeons who are finding new treatments for diabetes. I have two questions:
To combine infusions of islets from multiple pancreatic donors, is your group culturing human islets? If so, how long are the islets being cultured, and does the culturing have a deleterious effect on islet function and survival?
Second, your group published in Science the use of thymic stimulation to prevent allograft rejection without the use of immunosuppressive drugs. Is your group currently working on this technique for islet transplantation? DR. JAMES F. MARKMANN (Philadelphia, PA): First, I would like to thank all the discussants for their relevant comments. I would like to respond to Dr. Haller's comments first.
I agree completely that the issue here is really one of basic science. The main problem that we are facing is whether there are enough cadaveric pancreases to transplant the number of patients in need. Clearly, with 2 million type 1 diabetics and only 5,000 cadaveric pancreases a year, the answer is no, and other solutions must be sought. Just as it has taken us 30 years to begin the field of clinical islet transplantation, establishing it as a clinical reality where it can be applied to treat diabetic patients is going to require additional basic science research to address these problems.
Regarding the presence of other cells in the islet preparation, the islet preparation does have other non-endocrine cells, including immune cells, that we think probably assist in triggering rejection. However, compared to other allografts, the quantity is quite low, and the potential for graft-versushost disease, and unfortunately the potential for tolerance, is also low. So we need new strategies to accomplish this.
Dr. Brunicardi has mentioned the approach of intrathymic tolerance. This is an active area of research and one that is ongoing in our laboratory. We have performed islet transplants to the primate's thymus and they seem to function well there. Whether they induce tolerance is a question that we have not answered, but is of particular interest.
The primary question that each of the discussants mentioned is the issue of the number of donors required per recipient. I believe the issue is a basic science issue. There is good evidence that when we transplant islets, only about one third of the islets survive and engraft in recipient. If we could solve this simple problem, it would go a long way to make single donors capable of restoring euglycemia in a single recipient. There is convincing evidence reported by a number of laboratories that if you transfect antiapoptotic genes to islets, you can overcome a good deal of posttransplant loss of islet mass.
In the laboratory we have taken a slightly different approach by attempting to make individual islets function more efficiently. The approach used was to transfect islets with the human proinsulin gene so that the islets can produce more insulin. It seems somewhat simple-minded but was very effective. We utilized a model of human islets transplanted to immunodeficient mice. We found that transduction of human islets with the insulin gene rendered them twice as potent at reversing hyperglycemia, and thus, it required about half as many islets to cure diabetes in a mouse with islets treated in this way. I believe there will be solutions that come from further laboratory research that address these problems.
I would like to comment on two issues regarding multiple donors. The first is that each of the donors that we have used in this study, and that most centers use, are organs that have been turned down for use in whole organ transplantation. These are not optimal donors. In fact, the pancreata from which we obtain the best islet yields are generally steatotic and not well suited for whole organ transplantation. Many of the donors are older than 50 years of age, which is also usually an exclusion criteria for whole organ transplantation. At least at the present time, there is a difference in the population of pancreases that are best suited for whole organ transplantation and those that are optimal for islet isolation. Thus, the two techniques can coexist until the results of islet transplantation improve and this procedure becomes the standard therapy for type 1 diabetes.
Finally, regarding Dr. Brunicardi's comments about islet culture: we also consider this is a very important area of research. If we could maintain islets in vitro, multiple preparations could be combined. To date, we have only used short-term culture when two pancreases were available simultaneously, thereby allowing just enough time in culture for the second pancreas to be processed. Long-term culture will also be important to permit complete pretransplant assessment of graft quality, and also may reduce total graft volume, minimizing the potential for portal vein thrombosis.
Regarding the potential application of stem cells, I think this is an area that we are going to have to work toward but at present is not feasible. It will likely be many years before this approach can be applied successfully. Until then, I think that islet transplantation will have an important role in the treatment of type 1 diabetics.
